Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials | Zendy

David Wirta | Zendy; VanDenburgh | Zendy; Weng | Zendy; Scott M. Whitcup | Zendy; Kurstjens | Zendy; Beddingfield | Zendy

Open Access

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

Author(s) -

David Wirta,

VanDenburgh,

Weng,

Scott M. Whitcup,

Kurstjens,

Beddingfield

Publication year - 2011

Publication title -

clinical ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.025

H-Index - 56

eISSN - 1177-5483

pISSN - 1177-5467

DOI - 10.2147/opth.s17457

Subject(s) - bimatoprost , medicine , tolerability , adverse effect , eyelash , dermatology , ophthalmology , hypertrichosis , latanoprost , clinical trial , randomized controlled trial , erythema , intraocular pressure , surgery , genetics , biology

Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing intraoccular pressure (IOP) based on two double-masked, active-controlled clinical trials. Four additional long-term studies (≥12 months) were conducted; however, the aggregate safety profile of the six studies has not been reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research